GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (OTCPK:HSTO) » Definitions » Other Long-Term Liabilities

Histogen (Histogen) Other Long-Term Liabilities : $-0.00 Mil (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Histogen Other Long-Term Liabilities?

Histogen's other long-term liabilities for the quarter that ended in Sep. 2023 was $-0.00 Mil.

Histogen's quarterly other long-term liabilities increased from Mar. 2023 ($-0.00 Mil) to Jun. 2023 ($-0.00 Mil) but then stayed the same from Jun. 2023 ($-0.00 Mil) to Sep. 2023 ($-0.00 Mil).

Histogen's annual other long-term liabilities increased from Dec. 2020 ($-0.00 Mil) to Dec. 2021 ($-0.00 Mil) but then declined from Dec. 2021 ($-0.00 Mil) to Dec. 2022 ($-0.00 Mil).


Histogen Other Long-Term Liabilities Historical Data

The historical data trend for Histogen's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen Other Long-Term Liabilities Chart

Histogen Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Other Long-Term Liabilities
- - - -

Histogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Histogen Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.


Histogen Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Histogen's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Histogen (Histogen) Business Description

Industry
Traded in Other Exchanges
N/A
Address
10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
Executives
Joyce Reyes officer: See Remarks 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Richard W Pascoe director, officer: See Remarks C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Rochelle Fuhrmann director C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Susan Richards Windham-bannister director 78 BLANCHARD ROAD, BURLINGTON MA 01803
Moya Daniels officer: See Remarks 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Susan A. Knudson officer: See Remarks 9191 TOWNE CENTRE DRIVE, SUITE 400, SAN DIEGO CA 92121
Jonathan Jackson director, 10 percent owner C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Gail K Naughton officer: See Remarks C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Hugh Crean director C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Stephen Chang director 12912 CAMINO DEL VALLE, POWAY CA 92064
Brian Satz director C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Yizhuo Zhang director C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Martin Latterich officer: See Remarks C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Steven J Mento director C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Keith W Marshall officer: EVP, COO & CFO C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127

Histogen (Histogen) Headlines

From GuruFocus

Histogen to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 05-27-2022

Histogen Announces 1-for-20 Reverse Stock Split

By GuruFocusNews GuruFocusNews 06-01-2022

Histogen Announces 1-for-20 Reverse Stock Split

By GuruFocusNews GuruFocusNews 07-01-2022

Histogen Announces 1-for-20 Reverse Stock Split

By GuruFocusNews GuruFocusNews 06-21-2022